Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
Oliver KleinDamien KeeBo GaoBen MarkmanJessica Da Gama DuarteLuke QuigleyLouise JackettRichelle LinklaterAndrew StricklandClare ScottLinda MileshkinJodie PalmerMatteo CarlinoAndreas BehrenJonathan CebonPublished in: Journal for immunotherapy of cancer (2022)
Ipilimumab and nivolumab combination treatment has significant clinical activity with a favorable safety profile across a range of advanced rare gynecological malignancies and warrants further investigation in these tumor types.